Health Care

Bristol-Myers Squibb Co. (BMY) on Thursday reported second-quarter earnings of $916 million.

AstraZeneca's combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, sending its shares plunging on Thursday.

The Latest on the effort by congressional Republicans to pass a health care bill (all times local): 7:20 a.m.

A panel of Food and Drug Administration advisers voted against approving a new opioid painkiller with a unique feature for deterring abuse: It releases a deep-blue dye if someone tries to get high by crushing, chewing or snorting pills.

Republicans in the U.S. Senate fell short again on Wednesday in their effort to end Obamacare, rejecting a measure to repeal large portions of President Barack Obama's signature law that has provided health insurance to millions of Americans.

Ford Motor Co. is recalling nearly 117,000 vehicles because the bolts in the seat, seat belt or seat belt buckle may fracture.

U.S. health insurers want the federal government to shell out billions of dollars to continue funding for ObamaCare subsidies in order stabilize the insurance marketplace.

Former Rep. Dennis Kucinich (D-Ohio) on Wednesday said that a single-payer health care system, like ObamaCare, would benefit the American people more than one that depends on the free market, which is proposed in the latest GOP health care bill.

"Pharma Bro" Martin Shkreli (SHKREL'-ee) says on social media that he's being railroaded at his securities fraud trial, but he won't be defending himself in court.

One of the nation’s largest health insurers, Anthem (NYSE:ANTM), said Wednesday it may pull out of more state ObamaCare exchanges by 2018 – including those where it has already submitted rate proposals.

Former Eli Lilly USA President Alex Azar discusses Republican efforts to repeal and replace ObamaCare.

The prices of different products and services can grow at very different rates -- and these ones are getting pricey fast.

Drugmaker GlaxoSmithKline says it will halt some 30 clinical and pre-clinical programs as it reviews its research and development pipeline and focuses on improving efficiency.